Kidney Disease News and Research

RSS

Genzyme commences patient enrollment in Genz-112638 phase 3 trials

Genzyme Corporation today announced that the company has begun enrollment in the first of two global, multi-center, phase 3 trials of Genz-112638, a potential new oral therapy for Gaucher disease type 1. The two multi-national, multi-center trials are being conducted to evaluate the safety and efficacy of the small molecule.

21 Oct 2009

APP Pharmaceuticals to launch Chlorothiazide Sodium for Injection

APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to market Chlorothiazide Sodium for Injection, USP. APP expects to launch Chlorothiazide Sodium for Injection, USP in the fourth quarter of 2009.

21 Oct 2009

ImPACKD calls for raising awareness about the risks of calcium overuse in CKD patients

Most Canadians living with CKD have likely never spoken with their physicians about calcium and the serious health risks associated with its overuse. This is why Improving Patient Advocacy in Chronic Kidney Disease (ImPACKD), a group of CKD patients and caregivers committed to raising awareness about the risks of calcium overuse, is starting the conversation about the importance of knowing the limits and keeping them in check.

20 Oct 2009

Amgen receives Complete Response Letter for the Biologic License Applications for Prolia from FDA

Amgen Inc. today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter for the Biologic License Applications (BLA) for Prolia(TM) (denosumab) in the treatment and prevention of postmenopausal osteoporosis.

19 Oct 2009

Stem cell treatments could repair the kidney defects associated with Alport syndrome

Several cell-based therapy approaches could provide new treatments for patients with Alport syndrome, reports an upcoming paper in the Journal of the American Society of Nephrology (JASN). "Our study opens up many considerations of how new therapies related to the use of stem cells can be devised for our kidney patients with chronic disease," comments Raghu Kalluri, MD, PhD (Harvard Medical School, Boston, MA).

19 Oct 2009

Coronary angiography does not affect kidney functioning in CKD patients, reveals study

A screening test that measures whether a patient's heart is healthy enough for a kidney transplant is not as dangerous as once thought, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society Nephrology (CJASN).

19 Oct 2009

Study reveals the cost effectiveness of Rheos blood pressure lowering device

A study conducted by the University of Rochester Medical Center demonstrates that, for certain patient populations, an experimental device that lowers blood pressure may be a cost effective treatment. The implantable device, called Rheos, is in advanced stages of testing for individuals with drug resistant hypertension.

19 Oct 2009

Aethlon Medical to present data on HVC patients treated with its Hemopurifier at the 42nd ASN meeting

Aethlon Medical, Inc. disclosed today that clinical data resulting from the treatment of Hepatitis-C (HCV) infected patients with the Aethlon Hemopurifier® will be presented at the 42nd Annual Meeting & Scientific Exposition of the American Society of Nephrology (ASN).

15 Oct 2009

Genzyme ranked third on the global list for best employers

Genzyme Corporation announced today that scientists have again named the company a top employer in a survey ranking the reputations of biotechnology and pharmaceutical companies. Genzyme is ranked third on the global list of 575 companies, the second consecutive year it has achieved this position. Genzyme placed among the top 10 of all biotechnology and pharmaceutical companies in the world for the seventh year in a row.

15 Oct 2009

Study shows type 2 diabetes patients treated with ACTOplus met experience blood sugar reduction

A study, published online in the journal Current Medical Research and Opinion, showed that a greater percentage of patients with type 2 diabetes treated with the fixed-dose combination ACTOplus met® (pioglitazone HCl and metformin HCl) as initial therapy reached the study goal of hemoglobin A1c (HbA1c) of less than or equal to 7 percent compared to either component alone.

15 Oct 2009

Important issues facing nephrologists to be presented by Satellite Healthcare

Satellite Healthcare, one of the nation's first and leading providers of kidney dialysis services and a major sponsor of nephrology research, today announced that its chief researchers will present at The American Society of Nephrology (ASN) Renal Week 2009.

14 Oct 2009

American Recovery and Reinvestment Act funds to support research in numerous health areas

As part of the $5 billion in grants announced by President Obama, the National Institutes of Health has granted Kaiser Permanente more than $54 million over two years through the American Recovery and Reinvestment Act to conduct health research on a multitude of critical public and clinical health areas.

14 Oct 2009

Kaiser Permanente receives $54 million grant from NIH to conduct health research

14 Oct 2009

Thomson Reuters's NeoFax deployed at the University of Kansas Hospital for electronic neonatal drug dosing

The University of Kansas Hospital has deployed NeoFax(®) from Thomson Reuters to provide physicians, nurses, and pharmacy staff in its neonatal intensive care unit with electronic drug dosing, interaction checking, and reference information.

13 Oct 2009

Kidney Care Partners commends CBC for supporting reforms to improve access to quality kidney care

Kidney Care Partners - an alliance of patient advocates, dialysis professionals, care providers and manufacturers working together to improve quality of care for individuals with kidney disease and kidney failure - today applauded the Congressional Black Caucus (CBC) for supporting reforms that will improve patient access and choice in receiving quality kidney care.

13 Oct 2009

VitalProteinRx nutritional supplement for chronic kidney disease affected patients

VitalRemedyMD, a physician-established company, offers scientifically formulated integrative nutritional supplements designed to improve the quality of traditional healthcare. "We are proud that VitalProteinRx is now an integral part of Fresenius' armamentarium in helping patients with chronic kidney disease," stated Dr. Seth Baum, Founder of VitalRemedyMD.

13 Oct 2009

Wake Forest University School of Medicine honours researchers

Wake Forest University School of Medicine honored eight of its researchers with awards for excellence at the 13th Annual Research Awards Day Oct. 1.

12 Oct 2009

MEDLINE multi-purpose electronic database helps doctors care for their patients

Research funded by The Kidney Foundation of Canada and led by kidney specialists at Lawson Health Research Institute and The University of Western Ontario will make it possible for doctors to quickly and effectively access information relevant for patient care.

12 Oct 2009

WCMC-Q program highlights the importance of mental health to overall physical health

Mental health professionals from Weill Cornell Medical College in Qatar and the community highlighted the importance of mental health to overall physical health during a presentation Sunday as part of the medical college's recognition of World Mental Health Day.

12 Oct 2009

Plexxikon commences patient dosing in PLX3397 Phase 1 clinical trial

Plexxikon Inc. today announced that dosing of cancer patients with PLX3397 has started in a Phase 1 clinical trial. PLX3397 is a novel, oral investigational drug for treating multiple diseases, including metastatic cancer and rheumatoid arthritis.

9 Oct 2009

Kidney Disease News and Research

Genzyme commences patient enrollment in Genz-112638 phase 3 trials

APP Pharmaceuticals to launch Chlorothiazide Sodium for Injection

ImPACKD calls for raising awareness about the risks of calcium overuse in CKD patients

Amgen receives Complete Response Letter for the Biologic License Applications for Prolia from FDA

Stem cell treatments could repair the kidney defects associated with Alport syndrome

Coronary angiography does not affect kidney functioning in CKD patients, reveals study

Study reveals the cost effectiveness of Rheos blood pressure lowering device

Aethlon Medical to present data on HVC patients treated with its Hemopurifier at the 42nd ASN meeting

Genzyme ranked third on the global list for best employers

Study shows type 2 diabetes patients treated with ACTOplus met experience blood sugar reduction

Important issues facing nephrologists to be presented by Satellite Healthcare

American Recovery and Reinvestment Act funds to support research in numerous health areas

Kaiser Permanente receives $54 million grant from NIH to conduct health research

Thomson Reuters's NeoFax deployed at the University of Kansas Hospital for electronic neonatal drug dosing

Kidney Care Partners commends CBC for supporting reforms to improve access to quality kidney care

VitalProteinRx nutritional supplement for chronic kidney disease affected patients

Wake Forest University School of Medicine honours researchers

MEDLINE multi-purpose electronic database helps doctors care for their patients

WCMC-Q program highlights the importance of mental health to overall physical health

Plexxikon commences patient dosing in PLX3397 Phase 1 clinical trial

Free guide - Everything about renal proximal tubule cells eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News